"R&D Trends: Non-Small Cell Lung Cancer - Mutation Analyses Continue Driving Treatment Choices" Published
The 220 drugs in the non-small cell lung cancer (NSCLC) pipeline, is dominated by targeted therapies across all stages. There are a growing number of immunotherapies in development as drug developers look to target mutations and tumor specific antigens.
View full press release